feisty
Australian women in biotech are doing something that rarely gets the attention it deserves: converting basic science into clinical programs, commercial products, and companies that attract international capital. They're running ASX-listed therapeutics businesses, directing university spin-outs, and advising the funds that back early-stage life sciences. The sector is small by global standards, but the talent working inside it is not.
This list covers founders, researchers, clinical leaders, and executives across therapeutic drug development, diagnostics, medical devices, and agricultural biotechnology. It isn't exhaustive. It is a starting point for anyone trying to understand who holds influence in Australian biotech in 2026.
Founders building therapeutic companies
Fleur Doidge is the co-founder of a next-generation antibiotics platform commercialising compounds developed at the University of Queensland. Her company targets antimicrobial resistance, one of the most acutely underfunded areas in global drug development, and has advanced two candidates into preclinical programs.
Dr. Anna Blombery heads clinical genomics at the Peter MacCallum Cancer Centre in Melbourne and has co-founded a diagnostics spin-out that sequences tumour DNA to predict treatment response. Her work links directly to the cancer precision medicine pipeline several ASX-listed oncology companies draw on.
Carolyn Yeoh founded a bioprocessing company that manufactures cell and gene therapy components for clinical-stage customers who don't have in-house manufacturing capability. That model, contract development and manufacturing for advanced therapies, is one of the fastest-growing segments in Australian biotech right now.
Researchers whose work is reaching the clinic
Professor Jennifer Royle leads a structural biology group at the Walter and Eliza Hall Institute in Melbourne. Her team's cryo-electron microscopy work on protein targets has informed three separate drug discovery programs, two of which are now licensed to overseas pharmaceutical companies.
Dr. Rachael Rodgers directs reproductive biology research at the University of Adelaide. Her group's work on polycystic ovary syndrome has generated IP that underpins a hormone therapeutic currently in Phase 2 trials. Women's health has historically been underfunded in Australian biotech; her program is an exception.
Associate Professor Tara Roberts runs a translational immunology lab at the Garvan Institute in Sydney. Her research into autoimmune checkpoint pathways has attracted funding from both the National Health and Medical Research Council and a US-based biotech looking to in-license Australian IP.
Executives running listed and late-stage companies
Kate Munnings is the CEO of an ASX-listed oncology company developing a first-in-class oral cancer therapy. She joined from a global pharma role in London and brought with her the regulatory expertise the company's local management team lacked. The company completed a capital raise in late 2025 and is preparing for a Phase 3 readout.
Dr. Mel Thomson serves as Chief Scientific Officer at a listed agricultural biotech that develops drought-tolerant crop varieties. Her background in plant genomics is unusual in a sector dominated by human therapeutics, but agricultural biotech is a significant part of the Australian biotech economy and it often goes undercounted in these lists.
Naomi Li is CFO and acting COO at a medtech company commercialising a continuous glucose monitoring device designed specifically for non-diabetic metabolic monitoring. She moved into the role after a decade in healthcare investment banking and has been the main driver of the company's US market entry strategy.
Investors and advisors shaping capital flows
Dr. Sarah Sherburn is a partner at a Sydney-based life sciences fund that has backed 14 Australian biotech companies since 2018. Her focus is on platform technologies rather than single-asset companies, a strategy that has produced two successful trade sales and one ASX listing. She also sits on the board of BioCurate, the joint venture between the University of Melbourne and Monash University that commercialises research from both campuses.
Fiona Lawson is a managing director at a global investment bank covering Asia-Pacific life sciences. She has led equity capital markets transactions for ASX-listed biotech companies totalling over $800 million across 2023 and 2025. Her work sits at the intersection of capital markets and science commercialisation, which makes her one of the more practically influential figures on this list.
The women in Australian climate tech face a similar set of challenges: converting deep technical expertise into fundable companies while operating in a sector that global capital is still learning to read. Biotech and climate tech share more structural DNA than either community tends to acknowledge.
Why this sector still undercounts women
The numbers are improving, but slowly. Women hold roughly 35% of senior leadership roles at ASX-listed biotech companies, compared with about 28% across the broader ASX 300. That gap matters. It means the sector is slightly ahead of the ASX average, but still far from representative of the scientific workforce, where women make up over half of PhD graduates in biological sciences.
The bottleneck isn't at the lab bench. It's at the transition from researcher to founder, and from founder to funded CEO. That transition requires networks, capital introductions, and board-level credibility that are still distributed unevenly. Several of the women on this list built those networks through formal programs: the National Health and Medical Research Council leadership fellowships, the Australian Institute of Company Directors, and the BioMelbourne Network's emerging leaders cohort.
The pattern is consistent with what's visible across other technical sectors. Women in artificial intelligence research and company-building face the same structural gap between scientific credibility and commercial capital, and have navigated it through similar combinations of institutional support and peer networks. The solutions working in one sector tend to travel.
What to watch in the next two years
Three trends are creating new entry points for women in Australian biotech. First, the growth of contract research and manufacturing organisations means more operational leadership roles that don't require a scientific PhD. Second, the federal government's investment in domestic mRNA manufacturing capability is generating new executive and program management positions. Third, the surge in global licensing interest in Australian IP is increasing demand for people who can translate science for international counterparties.
The names on this list represent a cross-section of where Australian biotech talent sits in 2026. Some are already well known inside the sector. Others are not. All of them are worth knowing.